Results 21 to 30 of about 179,854 (236)

Assessing knowledge, attitudes, and practices and demand-side interventions for combating substandard and falsified medicines: a scoping review [PDF]

Journal of Pharmaceutical Policy and Practice
Background The proliferation of substandard and falsified medical products (SFM) poses a significant threat to public health globally. Despite rigorous surveillance and law enforcement efforts, risk of exposure to SFM is on the rise, notably through ...
Eishita Pal, Lubna Merchant, Alain K. Koffi, Reema Mehta, Jean Christophe Rusatira, Lev Kubiak, Henry Joseph Michtalik, Patrick Caubel, Saifuddin Ahmed   +8 more
doaj   +2 more sources

Substandard and falsified medicine recalls in the legitimate supply chain: a systematic review of evidence [PDF]

BMJ Open
Objectives To compare international substandard and falsified (SF) medicine recall trends from published research papers based on governmental databases, summarise the extent of the problem in the legitimate supply chain, and identify ways to manage the ...
Bernard D Naughton, Izabella Fryze
doaj   +2 more sources

Trade in substandard and falsified medicines [PDF]

, 2022
According to WHO, 10.5% of medicines in low- and middle-income countries are substandard or falsified (SF), which has a multidimensional impact on public health as well as severe economic and socioeconomic consequences. Constrained access, weak technical
Nhomsai Hagen, Cathrin Hauk, Lutz Heide
openaire   +2 more sources

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod

Drug Design, Development and Therapy, 2016
Jorge Correale,1 Erwin Chiquete,2 Alexey Boyko,3 Roy G Beran,4–6 Jorge Barahona Strauch,7,8 Snezana Milojevic,9 Nadina Frider101Department of Neurology, Raúl Carrea Institute for Neurological Research, Foundation for the Fight against Infant
Correale J, Chiquete E, Boyko A, Beran RG, Strauch JB, Milojevic S, Frider N   +6 more
doaj   +1 more source

Legal Uncertainty-The Gray Area around Substandard Medicines: Where Public Health Meets Law. [PDF]

Am J Trop Med Hyg, 2020
The WHO estimates that on average, 10.5% of the medicines in low- and middle-income countries (LMICs) are of poor quality,1 failing to meet standards for amounts of active ingredients(s), impurities, bioavailability, sterility, stability, packaging, etc ...
Olliaro E, Olliaro P, Ho CWL, Ravinetto R.   +3 more
europepmc   +2 more sources

The urgent need for African research collaboration on medicine quality [PDF]

Nature Communications
Substandard and falsified medicines threaten African health systems, yet research on this crisis is fragmented and concentrated in few countries, predominantly led by Global North institutions.
Fanqi Zeng, Simon Mariwah, Gerry Mshana, Daniel Amoako-Sakyi, Heather Hamill   +4 more
doaj   +2 more sources

Substandard medicines in resource‐poor settings: a problem that can no longer be ignored

Tropical Medicine and International Health, 2008
SummaryThe circulation of substandard medicines in the developing world is a serious clinical and public health concern. Problems include under or over concentration of ingredients, contamination, poor quality ingredients, poor stability and inadequate packaging. There are multiple causes.
J-M, Caudron, N, Ford, M, Henkens, C, Macé, R, Kiddle-Monroe, J, Pinel   +5 more
exaly   +4 more sources

Knowledge, attitudes and practices on substandard and falsified medicines for human and animal use in Wakiso district, Uganda [PDF]

Journal of Pharmaceutical Policy and Practice
Background Substandard and falsified medicines (SFMs) continue to pose a significant threat to public health globally. However, there is limited evidence on use of SFMs for both humans and animals particularly in low- and middle-income countries such as ...
David Musoke, Grace Biyinzika Lubega, Carol Esther Nabbanja, Filimin Niyongabo, Michael Obeng Brown, Elma Rejoice Banyen, Jody Winter, Claire Brandish, Kate Russell-Hobbs, Natasha Hamilton, Herbert Bush Aguma, Linda Gibson   +11 more
doaj   +2 more sources

Substandard medicines in Nepal: a crisis of access, equity, and a call for action. [PDF]

Front Public Health
Ghimire A.
europepmc   +3 more sources

Tinjauan Yuridis terhadap Bidan yang Memperdagangkan Obat Substandar dalam Perspektif Hukum Pidana dan Hukum Pidana Islam (Studi Putusan Nomor 1406/Pid.Sus/2020/PN Mdn)

Al-Manhaj, 2023
Substandard medicines trade is a very dangerous crime because it can harm society. This is the background for conducting research on Decision Number 1406/Pid.Sus/2020/Pn Mdn. The purpose of this research is to find out the review of criminal law against
Nafa Fadhilah Hasyim, Budi Sastra Panjaitan, Ramadani Ramadani   +2 more
doaj   +1 more source